TIFFANY MATSUO: Open Payments
NPI 1235834888 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$678 in 26 payments from 18 companies in 2025. Trend: 2023 $874 · 2024 $1,321 · 2025 $678
Food & beverage: $678
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $118 |
| Novartis Pharmaceuticals Corporation | 4 | $91 |
| BeOne Medicines USA, Inc. | 2 | $45 |
| Genentech USA, Inc. | 2 | $34 |
| GlaxoSmithKline, LLC. | 1 | $34 |
| Syndax Pharmaceuticals, Inc. | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $30 |
| PharmaEssentia USA Corporation | 1 | $30 |
| Iovance Biotherapeutics, Inc. | 1 | $29 |
Products named: SCEMBLIX, RYBREVANT, BRUKINSA, BLENREP, Onivyde, TECVAYLI, BESREMI, Amtagvi.
Industry payments across MD — which companies pay providers there.
